{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=10", "query": { "condition": "Drug Allergy", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 335, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T03:53:41.501Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01731015", "title": "Imaging Lung Function Using Oxygen Enhanced MRI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COPD", "Asthma", "Cystic Fibrosis", "Emphysema", "Small Airways Disease" ], "interventions": [ { "name": "Medical Grade Oxygen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hal C Charles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 15, "start_date": "2012-01", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731015" }, { "nct_id": "NCT01545440", "title": "A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 258, "start_date": "2012-03", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 70, "location_summary": "Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more", "locations": [ { "city": "Pell City", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545440" }, { "nct_id": "NCT00557180", "title": "Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Asthma", "Obesity" ], "interventions": [ { "name": "Beclomethasone dipropionate HFA", "type": "DRUG" }, { "name": "Tiotropium bromide", "type": "DRUG" }, { "name": "Salmeterol xinafoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-10", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 10, "location_summary": "San Diego, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00557180" }, { "nct_id": "NCT03432741", "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Adenocarcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Breast Carcinoma", "Refractory Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-03-27", "completion_date": "2022-10-03", "has_results": false, "last_update_posted_date": "2025-05-26", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03432741" }, { "nct_id": "NCT02871479", "title": "A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis", "Eczema" ], "interventions": [ { "name": "SAN007 5% cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SAN007 10% cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santalis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-04-21", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 5, "location_summary": "Austin, Texas • Bryan, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Bryan", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02871479" }, { "nct_id": "NCT07605806", "title": "Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy Volunteer", "Hypersensitivity Reactions", "Vancomycin" ], "interventions": [ { "name": "Vancomycin (IV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-05-21", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07605806" }, { "nct_id": "NCT00843544", "title": "Integrative Medicine Approach to the Management of Asthma in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Integrative Medicine", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 156, "start_date": "2006-03", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2009-02-13", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843544" }, { "nct_id": "NCT04313725", "title": "Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stevens-Johnson Syndrome", "Graft Versus Host Disease in Eye", "Sjogren's Syndrome", "Dry Eye" ], "interventions": [ { "name": "Tangible Boost", "type": "DEVICE" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Tangible Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-02-24", "completion_date": "2023-06-21", "has_results": true, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "Needham, Massachusetts", "locations": [ { "city": "Needham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04313725" }, { "nct_id": "NCT02758990", "title": "Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Rhinitis", "Rhinitis, Allergic", "Respiratory Sounds", "Dyspnea", "Headache", "Migraine Disorders", "Arthritis", "Arthralgia", "Anxiety", "Sleep Initiation and Maintenance Disorders", "Sleep Deprivation" ], "interventions": [ { "name": "Vitamin A", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin B6", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" }, { "name": "Nicotinamide", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D3", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "Broccoli", "type": "OTHER" }, { "name": "Spinach", "type": "OTHER" }, { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Coffee", "type": "OTHER" }, { "name": "Axon Eyewear", "type": "DEVICE" }, { "name": "Chocolate", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DEVICE" ], "sponsor": "Verifomics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-03", "completion_date": "2016-11-23", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758990" }, { "nct_id": "NCT06261957", "title": "A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Salbutamol HFA-134a", "type": "DRUG" }, { "name": "Salbutamol HFA-152a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 471, "start_date": "2024-05-31", "completion_date": "2025-09-02", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-30T03:53:41.501Z", "location_count": 38, "location_summary": "North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06261957" } ] }